✦ LIBER ✦

Oncogene amplification of C-Myc and N-Myc in cell lines established from patients with small cell lung cancer (SCLC) is associated with shortened survival

Book ID: 123011198
Publisher: Elsevier Science
Year: 1986
Tongue: English
Weight: 95 KB
Volume: 2
Category: Article
ISSN: 0169-5002
DOI: 10.1016/S0169-5002(86)80193-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Transfection of the C-Myc proto-oncogene

Transfection of the C-Myc proto-oncogene into classic small cell lung cancer (SCLC) cell lines causes phenotypic changes associated with C-MYC amplified variant SCLC lines

📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 96 KB

MYC family DNA amplification in 126 tumo

MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer

✍ Bruce E. Johnson; Edward Russell; Alfreda M. Simmons; Ruby Phelps; Seth M. Stein 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 834 KB

We identified 126 tumor cell lines established from patients with small cell cancer at the NCI-Navy Medical Oncology Branch from 1977 through 1992. Extensive clinical information was available on 96 patients from whom these cell lines were established. These patients comprised approximately one four

KIR2DL2/S2 and HLA-C C1C1 genotype is as

KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population

✍ Andrzej Wiśniewski; Renata Jankowska; Ewa Passowicz-Muszyńska; Elżbieta Wiśniews 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 329 KB

P-681 economic evaluation from a health

P-681 economic evaluation from a health care perspective of prophylactic use of antibiotics (AB) with and without granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC) patients at risk of febrile neutropenia (FN): a presentation of the study

✍ Timmer-Bonte, Anja N.; Adang, Eddy M.; Tjan-Heijnen, Vivianne C. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 186 KB

Biomarker Analyses and Final Overall Sur

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)

✍ Fukuoka, M.; Wu, Y.-L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.-S.; Sriur 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 241 KB

6570 POSTER Results for progression-free

6570 POSTER Results for progression-free survival (PFS) from two randomised, double-blind, multicentre phase III studies of bevacizumab in combination with platin-based chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) are comparable when analysed by similar populations and methodology

✍ Sandler, A.; Reck, M.; vonPawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB